US-UK Arrangement on Pharmaceutical Pricing Concluded
Summary
USTR announces the successful conclusion of a US-UK arrangement on pharmaceutical pricing, addressing long-standing trade imbalances in the pharmaceutical sector. The agreement aims to ensure trading partners contribute fairly to R&D costs while expanding affordable access to life-saving medicines and strengthening supply chains.
What changed
The United States and United Kingdom have concluded a bilateral arrangement on pharmaceutical pricing. The agreement addresses imbalances in US-UK pharmaceutical trade where American patients previously funded a disproportionate share of global R&D costs. Key commitments include improving UK patient access to medicines, strengthening supply chains, and promoting mutually beneficial trade.\n\nPharmaceutical companies operating in both US and UK markets should monitor implementation of pricing terms. The arrangement signals continued pressure on international pharmaceutical pricing structures and may influence similar negotiations with other trading partners.
What to do next
- Monitor for implementation details and compliance requirements under the arrangement
- Track future announcements from USTR and HHS regarding pharmaceutical pricing terms
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing
April
- Op-Ed by Ambassador Jamieson Greer: Another Fish Story From the WTO
- Ambassador Greer to Travel to Michigan and Ohio to Tour Manufacturing Plants and Meet with Manufacturing Workers and Industry Executives
- Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing
- Liberation Day One Year Later: Protecting American Jobs and Delivering Greater Market Access for American Farmers, Ranchers, and Manufacturers About Policy Offices Press Office Press Releases 2026 April Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing April 02, 2026
WASHINGTON — Today, United States Trade Representative Jamieson Greer, Health and Human Services Secretary Robert F. Kennedy, Jr, and Commerce Secretary Howard Lutnick issued the following statements announcing an arrangement on pharmaceutical pricing between the United States and the United Kingdom.
“President Trump is ensuring our trading partners pay their fair share for innovative pharmaceutical products, so that American patients are not shouldering the burden of funding research and development for the next generation of life-saving medicines,” said Ambassador Jamieson Greer. “Today’s Arrangement addresses long-standing imbalances in the U.S.-UK pharmaceutical trade while driving investment and development in both our countries. I thank the United Kingdom for its commitment to support positive patient outcomes by improving access to medicines, strengthening supply chains, and promoting mutually beneficial trade between our countries.”
“President Trump’s agreement with the United Kingdom is another big step toward ending a system that forces Americans to pay more so others can pay less,” said Health and Human Services Secretary Robert F. Kennedy, Jr. “American patients deserve the same affordable access to the medicines they need as patients in the UK.”
“Today’s agreement on pharmaceutical pricing is a major win for Americans and our innovation economy. It strengthens supply chains, expands Most Favored affordable access to life-saving drugs, and reinforces America as the world’s premier hub for life sciences investment,” said Secretary Howard Lutnick. “This agreement not only deepens our economic partnership with the United Kingdom and their leading pharmaceutical companies, but also helps ensure that tomorrow’s breakthroughs are accessible, affordable, and, manufactured on American soil.”
To read the text of the Arrangement Between the Government of the United States of America and the Government of the United Kingdom of Great Britain and Northern Ireland on Pharmaceutical Pricing, click here.
Stay in the Know
Get direct updates from USTR in your inbox. SUBSCRIBE
- 600 17th Street NW
- Washington, DC 20508
-
Related changes
Get daily alerts for USTR Press Releases
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USTR.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USTR Press Releases publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.